Clinical trials: Fatty Liver, Alcoholic
Non-Alcoholic Fatty Liver Disease, Immune Response
The Role of Immune Semaphorins in NAFLD
To goal is to identify semaphorins that are associated with NAFLD and to investigate their relationship with variable degrees of steatosis and fibrosis.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Immune Response, Biomarkers, Liver Fibrosis
- Trial name
- SepsisFAT (NCT04573543)
- Testing
- Evaluation of the degree of fibrosis and steatosis, Screening for the components of metabolic syndrome, Measurement of serum semaphorin concentrations
- Where
- Croatia
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- University Hospital for Infectious Diseases, Croatia
Non-alcoholic Fatty Liver Disease
To Explore the Effectiveness of Jing-Si Herbal Tea Against Non-alcoholic Fatty Liver Disease
The aim of this study is to explore the effectiveness of Jing-Si Herbal Tea on improving the Non-alcoholic fatty liver disease patients
- Trial name
- NCT05858138
- Testing
- Jing-Si Herbal Tea
- Where
- Taiwan
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Taichung Tzu Chi Hospital
Fat; Liver, NAFLD
The Effect of a High-fat vs. High-sugar Diet on Liver Fat Accumulation and Metabolism
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disease in the world. It is currently unclear why fat starts to accumulate in the liver, although both the amount and type of food consumed have been…
- Trial name
- NCT03145350
- Testing
- High-fat, low-carbohydrate, Low-fat, high-carbohydrate
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Heathy Participants
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD7503 in Japanese Healthy Participants.
The study will evaluate the safety, tolerability, and the pharmacokinetics (PK) of AZD7503 following multiple subcutaneous doses in healthy Japanese participants.
- Trial name
- NCT06093542
- Testing
- AZD7053
- Where
- Japan
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Non-alcoholic Fatty Liver Disease
Breath Analysis Using an Electronic Nose in Non Alcoholic Fatty Liver Disease
The purpose of this is to analyse human exhaled breath by means of a device called electronic nose(eNose) in patients with non-alcoholic fatty liver disease (NAFLD) as a way to non-invasive assessment of liver disease.This device…
- Trial name
- BEN (NCT02950610)
- Testing
- Breath analysis - electronic signature "Breath-print"
- Where
- United Kingdom
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University of Edinburgh
Obesity, Diabetes
Role of Dietary Fatty Acids in Fatty Liver and Insulin Resistance
The purpose of this study is to investigate whether substituting saturated fats with polyunsaturated fats reduces fatty liver and improves insulin action and other metabolic variables in abdominally obese subjects
- Conditions
- Obesity, Diabetes, Insulin Resistance, Fatty Liver
- Trial name
- HEPFAT (NCT01038102)
- Testing
- PUFA Diet, SFA diet
- Where
- Sweden
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Uppsala University
Non-Alcoholic Fatty Liver Disease
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BAR 502 in Healthy Subjects
This is a prospective, single-center, randomized, double-blind, placebo-controlled, single-ascending dose (SAD) phase 1 study to evaluate the safety and tolerability of single-ascending doses of BAR 502 in healthy male and female…
- Trial name
- NCT05203367
- Testing
- BAR502
- Where
- Portugal
- Volunteers
- healthy volunteers welcome
- Sponsor
- BAR Pharmaceuticals s.r.l.
Fatty Liver Disease, Fatty Infiltration
Fatty Liver Among Employees at Banha University
This was cross sectional study at Banha University Hospital among employees. Age of the subjects from 20-60 years old both males and females .All investigations done plus abdominal ultrasound for grading of fatty liver and dopler…
- Trial name
- fattyliver (NCT04367012)
- Testing
- Abdominal Ultrasound
- Where
- Egypt
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Benha University
Fibrosis, Inflammation
A 3-part Study to Evaluate Safety, Tolerability, Food Effect and Drug-drug Interactions of RXC007 in Healthy Volunteers
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of RXC007.
- Conditions
- Fibrosis, Inflammation, Idiopathic Pulmonary Fibrosis, Non-alcoholic Steatohepatitis
- Trial name
- NCT04931147
- Testing
- RXC007
- Where
- United Kingdom
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Redx Pharma Ltd
Type2 Diabetes, Fatty Liver, Nonalcoholic
Mechanism of Serum PRL in the Development of MAFLD
Metabolic associated fatty liver disease (MAFLD) has currently reached a worldwide epidemic. Serum PRL levels within or outside physiological range have been found to affect metabolic homeostasis differently.
- Conditions
- Type2 Diabetes, Fatty Liver, Nonalcoholic, Liver Fibrosis
- Trial name
- NCT05525884
- Testing
- non-invasive method, Fibroscan
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Shen Qu
NAFLD, Metabolic Syndrome
Dietary Supplementation With Butyrate in Individuals With Liver Steatosis and Metabolic Syndrome
This was a double-blind, randomized, placebo-controlled clinical study aiming to assess the effect of a food for special medical purposes with functional release containing calcium butyrate, zinc gluconate and vitamin D3 on liver…
- Trial name
- NCT06398522
- Testing
- Food for special medical purposes with calcium butyrate, zinc gluconate and vitamin D3
- Where
- Italy
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Bologna
Non-Alcoholic Fatty Liver Disease, Obesity
Effects of Dietary Fructose on Gut Microbiota and Fecal Metabolites in Obese Men and Postmenopausal Women: A Pilot Study
Non alcoholic fatty liver disease (NAFLD) is the most common cause of abnormal liver function tests in the U.S. (Browning, et al., 2004), ranging from steatosis to end-stage liver disease.
- Trial name
- NCT03339245
- Testing
- Fructose Solution (75 Grams), Glucose Solution (75 grams)
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Rockefeller University
Non-Alcoholic Fatty Liver Disease, Total Pancreatectomy
Hepatic Metabolic Changes in Response to Glucagon Infusion
The objective of the study is to investigate how exogenously administered glucagon affects hepatic lipid, glucose and protein metabolism as well as appetite, food intake and resting energy expenditure.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Total Pancreatectomy, Diabetes Mellitus
- Trial name
- NCT03526445
- Testing
- Glucagon, Saline
- Where
- Denmark
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Steno Diabetes Center Copenhagen
Hepatic Steatosis
Quantitative US for Hepatic Steatosis
The purpose of this study is to investigate the diagnostic performance of quantitative ultrasound imaging parameter for the assessment of hepatic steatosis in patients with non-alcoholic fatty liver disease using magnetic…
- Trial name
- NCT04180631
- Testing
- Quantitative ultrasound imaging parameter (QUS)
- Where
- South Korea
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Nonalcoholic Steatohepatitis (NASH), Primary Sclerosing Cholangitis (PSC)
Subcutaneous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects
CM-101 is developed as treatment for medical conditions involving inflammatory and fibrotic mechanisms such as non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).
- Conditions
- Nonalcoholic Steatohepatitis (NASH), Primary Sclerosing Cholangitis (PSC), Systemic Sclerosis (SSc)
- Trial name
- NCT06037577
- Testing
- CM-101
- Where
- Israel
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- ChemomAb Ltd.
Nonalcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease (NAFLD)
The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
The goal of this clinical trial is to learn if daily supplementation with Low-methoxy (LM) pectin (polysaccharides extracted from citrus peels), which are commonly found in the UK diet (not pharmacological agents), can reduce…
- Conditions
- Nonalcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease (NAFLD), MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
- Trial name
- PEC-MASLD (NCT07093346)
- Testing
- Pectin, Cocoa Powder, Magnetic Resonance Imaging with Contrast
- Where
- 3 sites in United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University of Nottingham
Non-alcoholic Fatty Liver Disease (NAFLD)
Improving Insulin Resistance To Treat Non-Alcoholic Fatty Liver Disease: A Pilot Study
Metformin is being compared to exercise and diet modifications. The researchers are interested in learning if the addition of metformin to lifestyle modifications is more helpful in treating the condition or disorder.
- Trial name
- NCT02457286
- Testing
- Metformin, Lifestyle modifications, Fibroscan device (Echosens)
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Northwell Health
Obesity
South Danish Obesity Initiative, Screening for Unrecognized Obesity Related Disease
People with BMI >30 kg/m2 will be included in at population-based cohort. Additionally, one control group with BMI 18.5-25 kg/m2 and one control group with BMI 25-30 kg/m2 will be included.
- Trial name
- SDOI (NCT05176132)
- Testing
- Life style intervention (dietician+ physiotherapist), Self management, No intervention
- Where
- Denmark
- Volunteers
- 2,700 people, healthy volunteers welcome
- Sponsor
- Claus Bogh Juhl
Healthy Participants
Study to Assess the Safety, Tolerability, and Pharmacokinetics (Movement of Drugs Within the Body) of AZD2693 in Healthy Participants
This Phase I, randomised, single-blind, placebo-controlled study has been designed to assess the safety, tolerability, and pharmacokinetics (PK) of AZD2693 following subcutaneous (SC) administration of AZD2693 in healthy…
- Trial name
- NCT05107336
- Testing
- AZD2693
- Where
- Japan
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
NAFLD, Insulin Resistance
Determination of Insulin-stimulated Hepatic Glucose Uptake by PET-CT Measurements
In the absence of excessive alcohol consumption, increased levels of fat in the liver (>5%) are diagnosed as non-alcoholic fatty liver (NAFL).
- Conditions
- NAFLD, Insulin Resistance, Overweight and Obesity
- Trial name
- ISGU (NCT04938544)
- Where
- Netherlands
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center